PSMA-PET Guided Radiotherapy

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2027

Conditions
Prostate Cancer
Interventions
RADIATION

PSMA -PET/CT simulation

"* PET/CT simulation.~* If no additional lesions detected: RT as planned per standard care.~* If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.~* If PSMA-PET/CT imaging consistent with widely metastatic disease (\>5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged."

RADIATION

Standard-care simulation

No PSMA-PET/CT as part of RT treatment planning.

Trial Locations (3)

Unknown

CSSSL - Cité de la Santé Laval, Laval

Centre Hospitalier de l'Université de Montréal, Montreal

CHU de Québec, Québec

All Listed Sponsors
collaborator

Progenics Pharmaceuticals, Inc.

INDUSTRY

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

NCT03525288 - PSMA-PET Guided Radiotherapy | Biotech Hunter | Biotech Hunter